Alectinib (42 in Figure 6) is a potent ALK inhibitor produced by Chugai Pharmaceutical Co., a Japanese company (Chuo, Tokyo) of the Hoffmann-La Roche group and approved by FDA and EMA in 2015 and 2017, respectively, for the treatment of advanced ALK-positive NSCLC after crizotinib treatment failure. Here, ALK is linked to non-small cell lung carcinoma.